Clinical Trial: Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease

Brief Summary: The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.

Detailed Summary:
Sponsor: Pfizer

Current Primary Outcome: Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients. CVR, humeral and carotid vasoreactivity will be measured in all patients at M0 and M3.

Original Primary Outcome: Same as current

Current Secondary Outcome: Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on endothelium dependant and independent vasomotoricity of humeral and / or common carotid artery (according to validation study) in lacunar patients.

Original Secondary Outcome: Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on endothelium dependant and independant vasomotricity of humeral and / or common carotid artery (according to validation study) in lacunar patients.

Information By: Pfizer

Dates:
Date Received: September 9, 2005
Date Started: June 2003
Date Completion:
Last Updated: March 13, 2008
Last Verified: April 2007